Belviq Weight Loss Enhancement

Good News!

Belviq has been placed on the Tricare Formulary. It is the only Weight Loss Medication that has been included.

$0 for active duty
$13 for non-active mail order
$17 for non-active retail

Belviq is a weight-loss drug that works by affecting chemicals in the brain that regulate appetite. When used together with both an improved diet and exercise, Belviq can be used to treat obesity. Sometimes Belviq can be used to treat obesity connected with diabetes, high blood pressure, or high cholesterol.

Belviq was approved in 2012 by the FDA for weight loss.

What is Belviq?

Belviq is made up of lorcaserin hydrochloride. It works by activating the serotonin 2C receptors in your brain, helping to satiate your appetite, and therefore reduce your food consumption.

Clinical Trials

Belviq underwent a Phase 3 clinical trial program in order to be approved by the FDA: BLOOM, BLOSSOM, and BLOOM-DM. Each trial program was controlled with a placebo group and randomized double-blind protocols. When combined with increased exercise and an improved diet, the clinical trials showed that patients who took Belviq experienced better weight loss than placebo groups with diet and exercise alone.

Belviq is intended to be used along with increased exercise and physical activity as well as a reduced-calorie diet.

Important Safety Information:

  • Belviq is not intended for use during pregnancy or for women who plan on becoming pregnant.
  • You should not take Belviq while breastfeeding.
  • Tell your doctor if you are also taking medicine for depression, mood, anxiety, migraine, the common cold, and other disorders. When combined with these types of drugs, Belviq may cause negative reactions and even life-threatening side effects.
  • Valvular heart disease: Some weight loss drugs have been linked to heart valve problems. Call your doctor right away if you experience trouble breathing, fatigue, dizziness, swelling of the legs, arms, feet, or ankles, or irregular or fast heartbeat while taking Belviq.
  • Report any problems with attention or memory to your doctor while taking Belviq.
  • Do not drive or operate heavy machinery while taking Belviq until you know how your body responds to the drug.
  • Taking too-high a dose of Belviq may cause mental problems such as feelings of euphoria, hallucinations, and disassociation (out of body experiences). You should not exceed the recommended dosage: 10 mg twice a day. Tell your doctor if you experience suicidal thoughts or behaviors while taking Belviq.
  • Hypoglycemia (low blood sugar): You should monitor your blood sugar levels carefully while taking Belviq. Some weight loss drugs have been shown to lower blood sugar in patients with type 2 diabetes who are also on medication to treat diabetes.
  • Priapism (painful erections): If you experience an erection lasting over 4 hours while taking Belviq, even if it is not painful, stop taking Belviz and call your doctor immediately or go an emergency room. Tell your doctor if you take medicine for erectile dysfunction before taking Belviq.
  • Slow heartbeat: Talk to your doctor if you have a history of heart block or a slow heartbeat, as Belviq may cause or worsen these conditions.
  • Blood Cell Count: Belviq may decrease the count of red or white blood cells. You doctor may conduct tests to check your blood cell count while taking Belviq.
  • Increased prolactin: Belviq may increase your body’s production of the hormone prolactin. Tell your doctor if your breasts begin to lactate or increase in size while taking Belviq.
  • Pulmonary Hypertension: Although rare, some weight loss drugs have been linked to increased pressure in the arteries contained in the lung, which can be life-threatening. It is unknown whether or not Belviq can contribute to this condition.
  • Common reaction in patients without diabetes: Dry mouth, headache, fatigue, dizziness, nausea, and constipation.
  • Common reactions in diabetic patients: Hypoglycemia, fatigue, headache, back pain, and cough.
  • After 12 weeks of treatment, your body’s response to Belviq should be evaluated to determine whether to continue therapy.